Loading clinical trials...
Loading clinical trials...
This is a Phase I/IIa study evaluating the safety and feasibility of \[89Zr\]Df-IAB2M as an immunoPET tracer for metastatic prostate cancer. Individuals participating in this study will have a FDG PET...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
ImaginAb, Inc.
NCT05939414 · Oligometastatic Prostate Cancer (OMPC)
NCT05751941 · Prostate Cancer, Metastatic Prostate Cancer
NCT07181161 · Metastatic Prostate Cancer
NCT06616597 · Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
NCT07209176 · Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions